In more detail what each of these biomarker tests are measuring and how they inform treatment decisions for my type...
According to the NCCN Guidelines for Patients with Follicular Lymphoma (2024), accurate testing is absolutely essential for both diagnosing and determining the right treatment approach. The guidelines emphasize that understanding your test results is important, and you should always discuss them thoroughly with your healthcare team.
From the provided guidelines, key biomarker tests typically include:
- Blood tests
- Bone marrow aspirate and biopsy
- Imaging studies
However, I notice that the provided guideline excerpts don't contain detailed information about specific biomarkers. To provide you with accurate information about biomarker testing, I would need to reference additional sections from the NCCN guidelines or other trusted sources like the Leukemia & Lymphoma Society's current recommendations.
What I can confidently tell you based on the NCCN Guidelines provided:
- Your healthcare team will use a combination of test results to create your treatment plan
- It's recommended to:
- Ask questions about your test results
- Wait to discuss results with your doctor for complete understanding
- Keep organized records of your test results
- Consider bringing someone with you to appointments to help take notes
Would you like me to:
- Focus on a specific type of biomarker test?
- Explain more about how to discuss test results with your healthcare team?
I want to ensure I provide you with accurate, source-based information rather than making general statements without proper citation.
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Grounded in NCCN Guidelines for Patients (Lymphomas) — the same guidelines oncologists use.
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated October 15, 2025. Informational only — not a substitute for your oncology team.
Question asked:
Can you explain in more detail what each of these biomarker tests are measuring and how they inform treatment decisions for my type of lymphoma?
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Source Guidelines
NCCN Guidelines for Patients (Lymphomas) (2026)Browse all NCCN Guidelines for Patients →Related Services
Services that may help with treatment for Lymphoma patients
Have your records handy? Add them to a private case for a deeper, personalized read →
Expert Webinars on Lymphoma
More questions about Lymphoma
- How do I make treatment decisions when facing uncertainty with Lymphoma
- Which biomarker tests (CD20, PD-L1) are recommended for my Lymphoma, and how will the results guide my diagnosis and...
- How does BRCA mutation status affect Lymphoma treatment decisions
- What follow-up tests do I need after Lymphoma treatment ends
- What is the myc biomarker? Does this relate to double hit
- What biomarker testing is recommended for early stage Lymphoma
- Recurred. How does this change my treatment choices, and are new targeted therapies using biomarkers (CD20, PD-L1)...
- What imaging tests are used to stage Lymphoma